Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EMA validates GSK’s application for myelofibrosis therapy
With a differentiated mechanism of action, momelotinib has inhibitory ability along three important signalling pathways, Janus kinase (JAK) 1, and JAK2 and activin A receptor type I (ACVR1).
With a differentiated mechanism of action, momelotinib has inhibitory ability along three important signalling pathways, Janus kinase (JAK) 1, and JAK2 and activin A receptor type I (ACVR1).
The multi-target, multi-year partnership will combine the clinical and commercial knowledge of Rallybio in rare diseases with AbCellera’s antibody discovery engine for identifying optimal clinical candidates and providing
Co-led by LYFE Capital and Novo Holdings, the financing round has also seen participation from existing investors OrbiMed Advisors and Versant Ventures. The latest funding will bring iECURE’s
The investigational new drug candidate reproxalap is a first-in-class small-molecule modulator of reactive aldehyde species (RASP) that are elevated in ocular and systemic inflammatory disease. It represents a
The second-generation PDT photosensitiser drug, REM-001 has undergone late-stage clinical development in previous clinical trials. The REM-001 therapy includes three parts, a laser light source, a light delivery
The patented oral, delayed release formulation of budesonide, Nefecon, has been designed as an enteric coated capsule to ensure that it stays intact until it reaches the Peyer’s
The application has been submitted for the combination of toripalimab, cisplatin and gemcitabine as the first-line treatment for locally recurrent or metastatic nasopharyngeal carcinoma (NPC) patients. The company
TAK-003 has been developed based on a live-attenuated dengue serotype 2 virus that offers the genetic backbone for all four vaccine viruses. It is currently being assessed to
The company developed the highly selective BTK inhibitor orelabrutinib for the treatment of autoimmune diseases and cancers. InnoCare co-founder, chairwoman and CEO Dr Jasmine Cui said: “Orelabrutinib’s NDA
Expected to be funded using nearly $35m of cash and cash equivalents at closing, the combined company will focus on advancing CalciMedica’s pipeline of first-in-class product candidates. The